| DIRECT COMPETITOR COMPARISON | |
| BIOD | LLY | NVO | SNY | Industry | | Market Cap: | 92.11M | 42.96B | 40.02B | 102.83B | 176.84M | | Employees: | 60 | 40,500 | 28,497 | 98,213 | 94 | | Qtrly Rev Growth (yoy): | N/A | 6.80% | 11.30% | 8.50% | 22.40% | | Revenue (ttm): | N/A | 21.11B | 10.26B | N/A | 42.63M | | Gross Margin (ttm): | N/A | 82.33% | 79.57% | 75.20% | 55.30% | | EBITDA (ttm): | -45.96M | 7.74B | 3.54B | N/A | -7.66M | | Oper Margins (ttm): | N/A | 30.97% | 29.92% | N/A | 2.08% | | Net Income (ttm): | -45.47M | -216.00M | 2.18B | N/A | N/A | | EPS (ttm): | -1.917 | -0.197 | 3.58 | N/A | -0.17 | | P/E (ttm): | N/A | N/A | 18.75 | N/A | 17.43 | | PEG (5 yr expected): | N/A | 4.05 | 1.21 | 2.61 | 1.01 | | P/S (ttm): | N/A | 2.04 | 3.93 | N/A | 4.43 |
|
| LLY = Eli Lilly & Co. | | NVO = Novo Nordisk A/S | | SNY = Sanofi-Aventis | | Industry = Drug Manufacturers - Other | |
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 56.85 | 0.53% | 57.54B | 12.40 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 48.18 | 1.69% | 13.93B | 16.12 | | Genzyme Corp. | GENZ | 49.98 | -0.58% | 13.26B | 28.49 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 46.59 | 0.71% | 41.93B | 18.02 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 50.64 | 0.78% | 9.03B | 1033.47 | | Teva Pharmaceutical Industries Limited | TEVA | 54.01 | 0.82% | 47.58B | 49.41 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 37.90 | 1.64% | 4.02B | 19.54 | | King Pharmaceuticals Inc. | KG | 11.72 | 0.43% | 2.91B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 17.99 | -1.15% | 5.50B | 110.37 | | Pfizer Inc. | PFE | 18.49 | -0.80% | 149.21B | 15.36 | | Johnson & Johnson | JNJ | 64.36 | 0.31% | 177.58B | 14.06 | | GlaxoSmithKline plc | GSK | 42.75 | 0.73% | 108.37B | 13.49 | | Sanofi-Aventis | SNY | 39.38 | -0.35% | 102.83B | N/A | | Novartis AG | NVS | 55.55 | -0.41% | 126.17B | 16.63 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 41.42 | -1.03% | N/A | N/A | | AstraZeneca plc | AZN | 46.30 | 1.49% | 67.13B | 9.30 | | Abbott Laboratories | ABT | 53.78 | -0.85% | 83.18B | 14.57 | | Bristol-Myers Squibb Co. | BMY | 25.14 | -0.08% | 49.80B | 13.01 |
|
| NEWS ON DIRECT COMPETITORS | |
| • | LLY | | UPDATE - Bristol, Pfizer to seek apixaban approval
Fri, Dec 4 -
at Reuters | | • | LLY | | [video] Six Banks Are Shut Down
Fri, Dec 4 -
at Forbes.com | | • | LLY | | UPDATE - FDA staff urge review of psychiatric drugs in kids
Fri, Dec 4 -
at Reuters | | • | LLY | | Antipsychotics, Diabetes & Kids
Fri, Dec 4 -
at The Wall Street Journal Online | | • | LLY | | FDA approves Lilly antipsychotic for teens
Fri, Dec 4 -
AP | | • | LLY | | FDA Approves Lilly's Zyprexa for Two Adolescent Indications
Fri, Dec 4 -
PR Newswire | | • | SNY | | Baxter Receives H1N1 Vaccine Order
Fri, Dec 4 -
Zacks.com | | • | SNY | | Lilly's Effient Proves Its Worth
Fri, Dec 4 -
Zacks.com | | • | SNY | | Good News for CytRx
Fri, Dec 4 -
Zacks.com | | • | SNY | | REO Speedwagon, The Game
Thu, Dec 3 -
at Forbes.com | | • | SNY | | Sanofi's Multaq Gains EU Approval
Thu, Dec 3 -
Zacks.com | | • | SNY | | Behind the Business: 3 Questions for Vical
Thu, Dec 3 -
at Motley Fool | | • | SNY | | Don't Doubt The Comcast Deal
Thu, Dec 3 -
at Forbes.com | | • | SNY | | Tough Sell: Sanofi Hands Out 750 Pink Slips to Sales Force
Wed, Dec 2 -
at The Wall Street Journal Online | | • | SNY | | H1N1: What It Means for Pharma
Wed, Dec 2 -
at Seeking Alpha | | • | NVO | | FDA Approves 10 mcg Dose of Vagifem(R) for the Treatment of Atrophic Vaginitis Due to Menopause
Wed, Dec 2 -
PR Newswire | | • | SNY | | Immunogen's Busy Month, Part II
Wed, Dec 2 -
at Seeking Alpha | | • | SNY | | The Man Who Will Run NBC
Wed, Dec 2 -
at Forbes.com | | • | SNY | | UBS ups Europe pharma rating to overweight
Wed, Dec 2 -
at MarketWatch | | • | NVO | | Increase In Patent Protection For Biologics Creates Significant Upside For Drug Development Enterprise Valuations
Sat, Nov 28 -
Wall Street Transcript | | • | NVO | | Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows
Fri, Nov 27 -
PR Newswire | | • | NVO | | The Complete List of Danish ADR Stocks
Fri, Nov 20 -
at Seeking Alpha | | • | NVO | | Doctors Cite Time, Low Reimbursement As Barriers To Providing Comprehensive Diabetes Care, Survey Results Show
Thu, Nov 19 -
PR Newswire | | • | NVO | | Can This Stock Go Higher?
Wed, Nov 18 -
at Motley Fool | | | All Headlines for these symbols... |
|
|
|
0.22% Nasdaq 
0.11 (2.76%) 
Competitors
